Celcuity, Inc. $CELC Shares Sold by Apis Capital Advisors LLC

Apis Capital Advisors LLC trimmed its position in Celcuity, Inc. (NASDAQ:CELC) by 22.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 602,000 shares of the company’s stock after selling 174,000 shares during the quarter. Celcuity makes up 10.5% of Apis Capital Advisors LLC’s holdings, making the stock its largest position. Apis Capital Advisors LLC owned about 1.30% of Celcuity worth $60,043,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Celcuity by 23.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,059,047 shares of the company’s stock valued at $101,717,000 after purchasing an additional 391,262 shares during the period. Choreo LLC bought a new stake in shares of Celcuity in the 3rd quarter valued at about $248,000. TD Asset Management Inc bought a new stake in shares of Celcuity in the 3rd quarter valued at about $3,596,000. Jennison Associates LLC bought a new stake in shares of Celcuity in the 4th quarter valued at about $22,911,000. Finally, Tudor Investment Corp ET AL bought a new stake in shares of Celcuity in the 3rd quarter valued at about $1,351,000. 63.33% of the stock is owned by institutional investors.

Celcuity Stock Performance

Shares of NASDAQ:CELC opened at $88.05 on Thursday. The company’s 50 day moving average price is $118.29 and its two-hundred day moving average price is $111.04. Celcuity, Inc. has a 12-month low of $11.27 and a 12-month high of $151.02. The firm has a market cap of $4.29 billion, a PE ratio of -22.58 and a beta of 0.10. The company has a quick ratio of 12.31, a current ratio of 12.31 and a debt-to-equity ratio of 6.04.

Celcuity (NASDAQ:CELC) last announced its earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.10. Equities research analysts predict that Celcuity, Inc. will post -3.69 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. HC Wainwright dropped their target price on shares of Celcuity from $185.00 to $145.00 and set a “buy” rating on the stock in a report on Wednesday, June 3rd. Weiss Ratings raised shares of Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. Guggenheim reaffirmed a “buy” rating on shares of Celcuity in a report on Wednesday, June 3rd. Citigroup reissued a “market outperform” rating on shares of Celcuity in a report on Thursday, May 28th. Finally, Wall Street Zen cut shares of Celcuity from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Eleven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Celcuity has a consensus rating of “Moderate Buy” and a consensus price target of $152.09.

Insider Buying and Selling

In other Celcuity news, Director Richard E. Buller sold 9,000 shares of the stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the transaction, the director owned 6,760 shares in the company, valued at $949,509.60. This represents a 57.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the transaction, the director owned 65,000 shares in the company, valued at approximately $9,144,200. The trade was a 27.78% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 37,000 shares of company stock worth $5,111,950. Company insiders own 13.33% of the company’s stock.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.